Analysis of human plasma proteins: A focus on sample collection and separation using free-flow electrophoresis

Expert Review of Proteomics

Volumn 5, Issue 4, 2008, Pages 571-587

  Nissum, Mikkel ^a   Foucher, Aude L ^a,b  

^a Becton Dickinson GmbH Germany   (Germany)

^b BD Technologies   (United States)

Author keywords

FFE; Fractionation; Free flow electrophoresis; Plasma; Proteomics; Sample collection; Separation; Serum

Indexed keywords

APOLIPOPROTEIN; BIOLOGICAL MARKER; BRAIN ABUNDANT MEMBRANE ATTACHED SIGNAL 1 PROTEIN; EDETIC ACID; INTER ALPHA TRYPSIN INHIBITOR; KIAA 0913 PROTEIN; L SELECTIN; MUCIN; NEBULIN; NERVE CELL ADHESION MOLECULE; NERVE CELL ADHESION MOLECULE L1; PEPTIDYL TRNA HYDROLASE 2 PROTEIN; PLASMA PROTEIN; PREALBUMIN; PROTEIN DEATH BOX POLYPEPTIDE 57; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULAR ENDOTHELIAL CADHERIN;

BLOOD ANALYSIS; ELECTROPHORESIS; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOCHEMISTRY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEOMICS; REVIEW; WESTERN BLOTTING;

BLOOD PROTEINS; ELECTROPHORESIS; HUMANS; PROTEOMICS;

EID: 51149121227     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.5.4.571     Document Type: Review

References (131)

1. Polanski M, Anderson NL. A list of candidate cancer biomarkers for targeted proteomics. Biomark. Insights 2, 1-48 (2006).
2. Sahab ZJ, Semaan SM, Sang QXA. Methodology and applications of disease biomarker identification in human serum. Biomark. Insights 2, 21-43 (2007).
3. Omenn GS, States DJ, Adamski M et al. Overview of the HUPO plasma proteome project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 5(13), 3226-3245 (2005). • Identification of the largest set of plasma proteins.
4. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell Proteomics 1(11), 845-867 (2002).
5. Rai AJ, Gelfand CA, Haywood BC et al. HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics 5(13), 3262-3277 (2005).
6. Yi J, Kim C, Gelfand CA. Inhibition of intrinsic proteolytic activities moderates preanalytical variability and instability of human plasma. J. Proteome Res. 6(5), 1768-1781 (2007). •• Preanalytical variability of plasma and the stabilization of the plasma proteome using protease inhibitors.
7. Li X, Gong Y, Wang Y et al. Comparison of alternative analytical techniques for the characterisation of the human serum proteome in HUPO Plasma Proteome Project. Proteomics 5(13), 3423-3441 (2005).
8. Misek DE, Kuick R, Wang H et al. A wide range of protein isoforms in serum and plasma uncovered by a quantitative intact protein analysis system. Proteomics 5(13), 3343-3352 (2005).
9. Yang Z, Hancock WS, Richmond T, Bonilla CL. A study of glycoproteins in human serum and plasma reference standards (HUPO) using multilectin affinity chromatography coupled with RPLC-MS/MS. Proteomics 5(13), 3353-3366 (2005).
10. Zhang H, Li X-j, Martin DB, Aebersold R. Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat. Biotech. 21(6), 660-666 (2003). • Reduction of sample complexity using an enrichment strategy towards glycoproteins.
11. Yang Z, Harris LE, Palmer-Toy DE, Hancock WS. Multilectin affinity chromatography for characterization of multiple glycoprotein biomarker candidates in serum from breast cancer patients. Clin. Chem. 52(10), 1897-1905 (2006).
12. Hakomori S. Glycosylation defining cancer malignancy: new wine in an old bottle. Proc. Natl Acad. Sci. USA 99(16), 10231-10233 (2002).
13. Burchell JM, Mungul A, Taylor-Papadimitriou J. O-linked glycosylation in the mammary gland: changes that occur during malignancy. J. Mammary Gland Biol. Neoplasia 6(3), 355-364 (2001).
14. Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat. Rev. Cancer 4(1), 45-60 (2004).
15. Moniaux N, Andrianifahanana M, Brand RE, Batra SK. Multiple roles of mucins in pancreatic cancer, a lethal and challenging malignancy. Br. J. Cancer 91(9), 1633-1638 (2004).
16. Odhiambo A, Perlman DH, Huang H et al. Identification of oxidative post-translational modification of serum albumin in patients with idiopathic pulmonary arterial hypertension and pulmonary hypertension of sickle cell anemia. Rapid Commun. Mass Spectrom. 21(14), 2195-2203 (2007).
17. Barelli S, Crettaz D, Thadikkaran L, Rubin O, Tissot J-D. Plasma/serum proteomics: pre-analytical issues. Expert Rev. Proteomics 4(3), 363-370 (2007).
18. Rai AJ, Vitzthum F. Effects of preanalytical variables on peptide and protein measurements in human serum and plasma: implications for clinical proteomics. Expert Rev. Proteomics 3(4), 409-426 (2006).
19. Tammen H, Schulte I, Hess R et al. Peptidomic analysis of human blood specimens: comparison between plasma specimens and serum by differential peptide display. Proteomics 5(13), 3414-3422 (2005).
20. Karsan A, Eigl BJ, Flibotte S et al. Analytical and preanalytical biases in serum proteomic pattern analysis for breast cancer diagnosis. Clin. Chem. 51(8), 1525-1528 (2005).
21. Villanueva J, Shaffer DR, Philip J et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J. Clin. Invest. 116(1), 271-284 (2006).
22. Marshall J, Kupchak P, Zhu W et al. Processing of serum proteins underlies the mass spectral fingerprinting of myocardial infarction. J. Proteome Res. 2(4), 361-372 (2003).
23. Zhang Z, Bast RC Jr, Yu Y et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 64(16), 5882-5890 (2004).
24. Villanueva J, Nazarian A, Lawlor K, Yi SS, Robbins RJ, Tempst P. A sequence-specific exopeptidase activity test (SSEAT) for "functional" biomarker discovery. Mol. Cell Proteomics 7(3), 509-518 (2008).
25. Hulmes J, Bethea D, Ho K et al. An investigation of plasma collection, stabilization, and storage procedures for proteomic analysis of clinical samples. Clin. Proteomics 1(1), 17-31 (2004).
26. Whiteaker JR, Zhang H, Eng JK et al. Head-to-head comparison of serum fractionation techniques. J. Proteome Res. 6(2), 828-836 (2007).
27. Hoffman SA, Joo WA, Echan LA, Speicher DW. Higher dimensional (Hi-D) separation strategies dramatically improve the potential for cancer biomarker detection in serum and plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 849(1-2), 43-52 (2007). •• Demonstration of increased proteome coverage using multidimensional separation strategies.
28. Jacobs JM, Adkins JN, Qian WJ et al. Utilizing human blood plasma for proteomic biomarker discovery. J. Proteome Res. 4(4), 1073-1085 (2005).
29. Bischoff R, Luider TM. Methodological advances in the discovery of protein and peptide disease markers. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 803(1), 27-40 (2004).
30. Graham DR, Elliott ST, Van Eyk JE. Broad-based proteomic strategies: a practical guide to proteomics and functional screening. J. Physiol. 563(Pt 1), 1-9 (2005).
31. Falk R, Ramstrom M, Stahl S, Hober S. Approaches for systematic proteome exploration. Biomol. Eng. 24(2), 155-168 (2007).
32. Alaiya A, Al-Mohanna M, Linder S. Clinical cancer proteomics: promises and pitfalls. J. Proteome Res. 4(4), 1213-1222 (2005).
33. Lee HJ, Lee EY, Kwon MS, Paik YK. Biomarker discovery from the plasma proteome using multidimensional fractionation proteomics. Curr. Opin. Chem. Biol. 10(1), 42-49 (2006).
34. Qian W-J, Jacobs JM, Liu T, Camp DG II, Smith RD. Advances and challenges in liquid chromatography-mass spectrometry-based proteomics profiling for clinical applications. Mol. Cell Proteomics 5(10), 1727-1744 (2006).
35. Rose K, Bougueleret L, Baussant T et al. Industrial-scale proteomics: from liters of plasma to chemically synthesized proteins. Proteomics 4(7), 2125-2150 (2004).
36. Pernemalm M, Orre LM, Lengqvist J, Wikstroem P, Lewensohn R, Lehtioe J. Evaluation of three principally different intact protein prefractionation methods for plasma biomarker discovery. J. Proteome Res. 7(7), 2712-2722 (2008).
37. Anderson L, Anderson NG. High resolution two-dimensional electrophoresis of human plasma proteins. Proc. Natl Acad. Sci. USA 74(12), 5421-5425 (1977).
38. Celis JE, Celis P, Ostergaard M et al. Proteomics and immunohistochemistry define some of the steps involved in the squamous differentiation of the bladder transitional epithelium: a novel strategy for identifying metaplastic lesions. Cancer Res. 59(12), 3003-3009 (1999).
39. Celis JE, Wolf H, Østergaard M. Bladder squamous cell carcinoma biomarkers derived from proteomics. Electrophoresis 21(11), 2115-2121 (2000).
40. Lee I-N, Chen C-H, Sheu J-C et al. Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics 6(9), 2865-2873 (2006).
41. Sheng S, Chen D, Van Eyk JE. Multidimensional liquid chromatography separation of intact proteins by chromatographic focusing and reversed phase of the human serum proteome: optimization and protein database. Mol. Cell Proteomics 5(1), 26-34 (2006).
42. Qin S, Ferdinand AS, Richie JP, O'Leary MP, Mok SC, Liu BCS. Chromatofocusing fractionation and two-dimensional difference gel electrophoresis for low abundance serum proteins. Proteomics 5(12), 3183-3192 (2005).
43. Sahab ZJ, Suh Y, Sang QXA. Isoelectric point-based prefractionation of proteins from crude biological samples prior to two-dimensional gel electrophoresis. J. Proteome Res. 4(6), 2266-2272 (2005).
44. Marshall J, Jankowski A, Furesz S et al. Human serum proteins preseparated by electrophoresis or chromatography followed by tandem mass spectrometry. J. Proteome Res. 3(3), 364-382 (2004).
45. Martosella J, Zolotarjova N, Liu H, Nicol G, Boyes BE. Reversed-phase high-performance liquid chromatographic prefractionation of immunodepleted human serum proteins to enhance mass spectrometry identification of lower-abundant proteins. J. Proteome Res. 4(5), 1522-1537 (2005).
46. Morris DL, Sutton JN, Harper RG, Timperman AT. Reversed-phase HPLC separation of human serum employing a novel saw-tooth gradient: toward multidimensional proteome analysis. J. Proteome Res. 3(6), 1149-1154 (2004).
47. Kuhn E, Wu J, Karl J, Liao H, Zolg W, Guild B. Quantification of C-reactive protein in the serum of patients with rheumatoid arthritis using multiple reaction monitoring mass spectrometry and C-labeled peptide standards. Proteomics 4(4), 1175-1186 (2004).
48. Pieper R, Gatlin CL, McGrath AM et al. Characterization of the human urinary proteome: a method for high-resolution display of urinary proteins on two-dimensional electrophoresis gels with a yield of nearly 1400 distinct protein spots. Proteomics 4(4), 1159-1174 (2004).
49. Barnea E, Sorkin R, Ziv T, Beer I, Admon A. Evaluation of prefractionation methods as a preparatory step for multidimensional based chromatography of serum proteins. Proteomics 5(13), 3367-3375 (2005).
50. Zuo X, Speicher DW. Comprehensive analysis of complex proteomes using microscale solution isoelectrofocusing prior to narrow pH range two-dimensional electrophoresis. Proteomics 2(1), 58-68 (2002).
51. Heller M, Michel PE, Morier P et al. Two-stage off-gel isoelectric focusing: protein followed by peptide fractionation and application to proteome analysis of human plasma. Electrophoresis 26(6), 1174-1188 (2005).
52. Michel PE, Crettaz D, Morier P et al. Proteome analysis of human plasma and amniotic fluid by focusing followed by nano-LC-MS/MS. Electrophoresis 27(5-6), 1169-1181 (2006).
53. Tu CJ, Dai J, Li SJ et al. High-sensitivity analysis of human plasma proteome by immobilized isoelectric focusing fractionation coupled to mass spectrometry identification. J. Proteome Res. 4(4), 1265-1273 (2005).
54. Pieper R, Su Q, Gatlin CL, Huang S-T, Anderson NL, Steiner S. Multi-component immunoaffinity subtraction chromatography: an innovative step towards a comprehensive survey of the human plasma proteome. Proteomics 3(4), 422-432 (2003).
55. Zolotarjova N, Martosella J, Nicol G, Bailey J, Boyes BE, Barrett WC. Differences among techniques for high-abundant protein depletion. Proteomics 5(13), 3304-3313 (2005).
56. Huang L, Harvie G, Feitelson JS et al. Immunoaffinity separation of plasma proteins by IgY microbeads: meeting the needs of proteomic sample preparation and analysis. Proteomics 5(13), 3314-3328 (2005).
57. Liu T, Qian W-J, Mottaz HM et al. Evaluation of multiprotein immunoaffinity subtraction for plasma proteomics and candidate biomarker discovery using mass spectrometry. Mol. Cell Proteomics 5(11), 2167-2174 (2006). • Reduction of sample complexity using immunoaffinity depletion.
58. Liu T, Qian WJ, Gritsenko MA et al. Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry. J. Proteome Res. 4(6), 2070-2080 (2005).
59. Zhang H, Aebersold R. Isolation of glycoproteins and identification of their N-linked glycosylation sites. Methods Mol. Biol. 328, 177-185 (2006).
60. Esteva FJ, Cheli CD, Fritsche H et al. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Res. 7(4), R436-R443 (2005).
61. Liu T, Qian WJ, Strittmatter EF et al. High-throughput comparative proteome analysis using a quantitative cysteinyl-peptide enrichment technology. Anal. Chem. 76(18), 5345-5353 (2004).
62. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature 422(6928), 198-207 (2003). • Recent advances and perspectives in mass spectrometry-based proteomics.
63. Adkins JN, Varnum SM, Auberry KJ et al. Toward a human blood serum proteome: analysis by multidimensional separation coupled with mass spectrometry. Mol. Cell Proteomics 1(12), 947-955 (2002).
64. Echan LA, Tang H-Y, Ali-Khan N, Lee K, Speicher DW. Depletion of multiple high-abundance proteins improves protein profiling capacities of human serum and plasma. Proteomics 5(13), 3292-3303 (2005).
65. Tang H-Y, Ali-Khan N, Echan LA, Levenkova N, Rux John J, Speicher DW. A novel four-dimensional strategy combining protein and peptide separation methods enables detection of low-abundance proteins in human plasma and serum proteomes. Proteomics 5(13), 3329-3342 (2005).
66. Liu H, Sadygov RG, Yates JR. A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal. Chem. 76(14), 4193-4201 (2004).
67. Wu L, Han DK. Overcoming the dynamic range problem in mass spectrometry-based shotgun proteomics. Expert Rev. Proteomics 3(6), 611-619 (2006).
68. Tabb DL, MacCoss MJ, Wu CC, Anderson SD, Yates JR. Similarity among tandem mass spectra from proteomic experiments: detection, significance, and utility. Anal. Chem. 75(10), 2470-2477 (2003).
69. Smith RD, Anderson GA, Lipton MS et al. An accurate mass tag strategy for quantitative and high-throughput proteome measurements. Proteomics 2(5), 513-523 (2002).
70. May D, Fitzgibbon M, Liu Y et al. A platform for accurate mass and time analyses of mass spectrometry data. J. Proteome Res. 6(7), 2685-2694 (2007).
71. Ong S-E, Blagoev B, Kratchmarova I et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell Proteomics 1(5), 376-386 (2002).
72. Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotech. 17(10), 994-999 (1999).
73. Zhang Y, Wolf-Yadlin A, Ross PL et al. Time-resolved mass spectrometry of tyrosine phosphorylation sites in the epidermal growth factor receptor signaling network reveals dynamic modules. Mol. Cell Proteomics 4(9), 1240-1250 (2005).
74. DeSouza L, Diehl G, Rodrigues MJ et al. Search for cancer markers from endometrial tissues using differentially labeled tags iTRAQ and cICAT with multidimensional liquid chromatography and tandem mass spectrometry. J. Proteome Res. 4(2), 377-386 (2005).
75. Schmidt A, Kellermann J, Lottspeich F. A novel strategy for quantitative proteomics using isotope-coded protein labels. Proteomics 5(1), 4-15 (2005).
76. Wang W, Zhou H, Lin H et al. Quantification of proteins and metabolites by mass spectrometry without isotopic labeling or spiked standards. Anal. Chem. 75(18), 4818-4826 (2003).
77. Chelius D, Bondarenko PV. Quantitative profiling of proteins in complex mixtures using liquid chromatography and mass spectrometry. J. Proteome Res. 1(4), 317-323 (2002).
78. Fang R, Elias DA, Monroe ME et al. Differential label-free quantitative proteomic analysis of Shewanella oneidensis cultured under aerobic and suboxic conditions by accurate mass and time tag approach. Mol. Cell Proteomics 5(4), 714-725 (2006).
79. Lee S-W, Berger SJ, Martinovic S et al. Direct mass spectrometric analysis of intact proteins of the yeast large ribosomal subunit using capillary LC/FTICR. Proc. Natl Acad. Sci. USA 99(9), 5942-5947 (2002).
80. Bogdanov B, Smith RD. Proteomics by FTICR mass spectrometry: top down and bottom up. Mass Spectrom. Rev. 24(2), 168-200 (2005).
81. Mikesh LM, Ueberheide B, Chi A et al. The utility of ETD mass spectrometry in proteomic analysis. Biochim. Biophys. Acta 1764(12), 1811-1822 (2006).
82. Udeshi ND, Shabanowitz J, Hunt DF, Rose KL. Analysis of proteins and peptides on a chromatographic timescale by electron-transfer dissociation MS. FEBS J. 274(24), 6269-6276 (2007).
83. Anderson NL. Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J. Physiol. 563(1), 23-60 (2005).
84. Anderson NL, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol. Cell Proteomics 5(4), 573-588 (2006).
85. Washburn MP, Wolters D, Yates JR. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat. Biotech. 19(3), 242-247 (2001).
86. Shen Y, Jacobs JM, Camp DG II et al. UltraHhigh-efficiency strong cation exchange LC/RPLC/MS/MS for high dynamic range characterization of the human plasma proteome. Anal. Chem. 76(4), 1134-1144 (2004).
87. Peng J, Elias JE, Thoreen CC, Licklider LJ, Gygi SP. Evaluation of multidimensional chromatography coupled with tandem mass spectrometry (LC/LC-MS/MS) for large-scale protein analysis: the yeast proteome. J. Proteome Res. 2(1), 43-50 (2003).
88. Jin WH, Dai J, Li SJ, Xia QC, Zou HF, Zeng R. Human plasma proteome analysis by multidimensional chromatography prefractionation and linear ion trap mass spectrometry identification. J. Proteome Res. 4(2), 613-619 (2005).
89. Malmstrom J, Lee H, Nesvizhskii AI et al. Optimized peptide separation and identification for mass spectrometry based proteomics via free-flow electrophoresis. J. Proteome Res. 5(9), 2241-2249 (2006).
90. Giddings JC. Concepts and comparisons in multidimensional separation. J. High Resolut. Chromatogr. 10(5), 319-323 (1987).
91. Moritz RL, Simpson RJ. Liquid-based free-flow electrophoresis-reversed- phase HPLC: a proteomic tool. Nat. Methods 2(11), 863-873 (2005). •• Introduction to free-flow eletrophoresis (FFE).
92. Kohlheyer D, Eijkel JCT, van den Berg A, Schasfoort RBM. Miniaturizing free-flow electrophoresis - a critical review. Electrophoresis 29(5), 977-993 (2008).
93. Hartmann K, Nissum M, Wildgruber R, Weber G, Eckerskorn C. Keeping proteins in solution: interval free-flow zone electrophoretic separation of a total protein extract from HeLa cells. J. Biomol. Tech. 18(1), 54 (2007).
94. Nissum M, Kronbauer S, Wildgruber R, Weber G, Eckerskorn C. Separation of peptides and modified peptides using free-flow electrophoresis. J. Biomol. Tech. 19(1), 63 (2008).
95. O'Mullan P, Craft D, Kim C, Gelfand CA. Separation and partial characterization of dipeptidyl peptidase IV isoforms by free flow electrophoresis and MALDI-TOF MS. Presented at: 55th ASMS Conference on Mass Spectrometry and Allied Topics. IN, USA, 3-7 June 2007.
96. Kuzyk MA, Elliot M, Hardie D et al. Top-down analysis of histones separated by free flow electrophoresis. Presented at: US HUPO 3rd Annual Conference. WA, USA, 5-8 March 2007.
97. Drews O, Wildgruber R, Zong C et al. Mammalian proteasome subpopulations with distinct molecular compositions and proteolytic activities. Mol. Cell Proteomics 6(11), 2021-2031 (2007).
98. O'Mullan P, Kim C, Hardie D, Gelfand CA. Separation and characterization of dipeptidyl peptidase IV isoforms by free flow electrophoresis. Presented at: US HUPO 3rd Annual Conference. WA, USA, 5-8 March 2007.
99. Moritz RL, Clippingdale AB, Kapp EA et al. Application of 2-D free-flow electrophoresis/RP-HPLC for proteomic analysis of human plasma depleted of multi high-abundance proteins. Proteomics 5(13), 3402-3413 (2005). • Combined FFE and reversed-phase-HPLC workflow for the separation of human plasma.
100. Xie H, Bandhakavi S, Griffin TJ. Evaluating preparative isoelectric focusing of complex peptide mixtures for tandem mass spectrometry-based proteomics: a case study in profiling chromatin-enriched subcellular fractions in Saccharomyces cerevisiae. Anal. Chem. 77(10), 3198-3207 (2005).
101. Xie H, Rhodus NL, Griffin RJ, Carlis JV, Griffin TJ. A catalogue of human saliva proteins identified by free flow electrophoresis-based peptide separation and tandem mass spectrometry. Mol. Cell Proteomics 4(11), 1826-1830 (2005).
102. Nissum M, Kuhfuss S, Hauptmann M et al. Two-dimensional separation of human plasma proteins using iterative free-flow electrophoresis. Proteomics 7(23), 4218-4227 (2007). •• Combination of two FFE separation dimensions for plasma separation.
103. Immler D, Greven S, Reinemer P. Targeted proteomics in biomarker validation: detection and quantification of proteins using a multi-dimensional peptide separation strategy. Proteomics 6(10), 2947-2958 (2006).
104. Wang Y, Hancock WS, Weber G, Eckerskorn C, Palmer-Toy D. Free flow electrophoresis coupled with liquid chromatography-mass spectrometry for a proteomic study of the human cell line (K562/CR3). J. Chromatogr. A 1053(1-2), 269-278 (2004).
105. Hoffmann P, Ji H, Moritz RL et al. Continuous free-flow electrophoresis separation of cytosolic proteins from the human colon carcinoma cell line LIM 1215: a non two-dimensional gel electrophoresis-based proteome analysis strategy. Proteomics 1(7), 807-818 (2001).
106. Hoffmann P, Olayioye MA, Moritz RL et al. Breast cancer protein StarD10 identified by three-dimensional separation using free-flow electrophoresis, reversed-phase high-performance liquid chromatography, and sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Electrophoresis 26(6), 1029-1037 (2005).
107. Moritz RL, Ji H, Schutz F et al. A proteome strategy for fractionating proteins and peptides using continuous free-flow electrophoresis coupled off-line to reversed-phase high-performance liquid chromatography. Anal. Chem. 76(16), 4811-4824 (2004).
108. Moritz RL, Skandarajah AR, Ji H, Simpson RJ. Proteomic analysis of colorectal cancer: prefractionation strategies using two-dimensional free-flow electrophoresis. Comp. Funct. Genomics 6(4), 236-243 (2005).
109. Xie H, Onsongo G, Popko J et al. Proteomics analysis of cells in whole saliva from oral cancer patients via value-added three-dimensional peptide fractionation and tandem mass spectrometry. Mol. Cell Proteomics 7(3), 486-498 (2008).
110. Brunner E, Ahrens CH, Mohanty S et al. A high-quality catalog of the Drosophila melanogaster proteome. Nat. Biotech. 25(5), 576-583 (2007). • Large-scale proteome characterization using several separation strategies.
111. Xie H, Bandhakavi S, Roe MR, Griffin TJ. Preparative peptide isoelectric focusing as a tool for improving the identification of lysine-acetylated peptides from complex mixtures. J. Proteome Res. 6(5), 2019-2026 (2007).
112. Bodenmiller B, Malmstrom J, Gerrits B et al. PhosphoPep - a phosphoproteome resource for systems biology research in Drosophila Kc167 cells. Mol. Syst. Biol. 3, 139 (2007).
113. Barkla BJ, Vera-Estrella R, Pantoja O. Enhanced separation of membranes during free flow zonal electrophoresis in plants. Anal. Chem. 79(14), 5181-5187 (2007).
114. Senis YA, Tomlinson MG, Garcia A et al. A comprehensive proteomics and genomics analysis reveals novel transmembrane proteins in human platelets and mouse megakaryocytes including G6b-B, a novel immunoreceptor tyrosine-based inhibitory motif protein. Mol. Cell Proteomics 6(3), 548-564 (2007).
115. Sengelov H, Nielsen MH, Borregaard N. Separation of human neutrophil plasma membrane from intracellular vesicles containing alkaline phosphatase and NADPH oxidase activity by free flow electrophoresis. J. Biol. Chem. 267(21), 14912-14917 (1992).
116. Painter RG, Valentine VG, Lanson NA Jr et al. CFTR expression in human neutrophils and the phagolysosomal chlorination defect in cystic fibrosis. Biochemistry 45(34), 10260-10269 (2006).
117. Zischka H, Braun RJ, Marantidis EP et al. Differential analysis of Saccharomyces cerevisiae mitochondria by free flow electrophoresis. Mol. Cell Proteomics 5(11), 2185-2200 (2006).
118. Zischka H, Weber G, Weber PJ et al. Improved proteome analysis of Saccharomyces cerevisiae mitochondria by free-flow electrophoresis. Proteomics 3(6), 906-916 (2003).
119. Eubel H, Lee CP, Kuo J, Meyer EH, Taylor NL, Millar AH. Free-flow electrophoresis for purification of plant mitochondria by surface charge. Plant J. 52(3), 583-594 (2007).
120. Mohr H, Völkl A. Isolation of peroxisomal subpopulations from mouse liver by immune free-flow electrophoresis. Electrophoresis 23(13), 2130-2137 (2002).
121. Weber G, Islinger M, Weber P, Eckerskorn C, Volkl A. Efficient separation and analysis of peroxisomal membrane proteins using free-flow isoelectric focusing. Electrophoresis 25(12), 1735-1747 (2004).
122. Stalder D, Haeberli A, Heller M. Evaluation of reproducibility of protein identification results after multidimensional human serum protein separation. Proteomics 8(3), 414-424 (2008).
123. Cho SY, Lee EY, Lee JS et al. Efficient prefractionation of low-abundance proteins in human plasma and construction of a two-dimensional map. Proteomics 5(13), 3386-3396 (2005).
124. Zhou M, Lucas DA, Chan KC et al. An investigation into the human serum "interactome". Electrophoresis 25(9), 1289-1298 (2004).
125. Petricoin EF, Liotta LA. SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr. Opin. Biotechnol. 15(1), 24-30 (2004).
126. Gundry RL, Fu Q, Jelinek CA, Van Eyk JE, Cotter RJ. Investigation of an albumin-enriched fraction of human serum and its albuminome. Proteomics Clin. Appl. 1(1), 73-88 (2007).
127. Kirmiz C, Li B, An HJ et al. A serum glycomics approach to breast cancer biomarkers. Mol. Cell Proteomics 6(1), 43-55 (2007).
128. Krueger KE, Srivastava S. Posttranslational protein modifications: current implications for cancer detection, prevention, and therapeutics. Mol. Cell Proteomics 5(10), 1799-1810 (2006).
129. Keller A, Eng J, Zhang N, Li XJ, Aebersold R. A uniform proteomics MS/MS analysis platform utilizing open XML file formats. Mol. Syst. Biol. 1, 2005.0017 (2005).
130. Nesvizhskii AI, Keller A, Kolker E, Aebersold R. A statistical model for identifying proteins by tandem mass spectrometry. Anal. Chem. 75(17), 4646-4658 (2003).
131. Hupo - Research Projects - Plasma Proteome Project www.hupo.org/research/ hppp